1
|
Carrillo-García J, Lacerenza S, Hindi N, García IC, Marquina G, Cano Cano JM, Trufero JM, Sevillano Tripero AR, Luis García T, Cuesta Rioboo MJ, Moura DS, Renshaw M, Mondaza-Hernández JL, Di Lernia D, Gutierrez A, Martin-Broto J. Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain. Ther Adv Med Oncol 2024; 16:17588359231220611. [PMID: 38205079 PMCID: PMC10777772 DOI: 10.1177/17588359231220611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 11/21/2023] [Indexed: 01/12/2024] Open
Abstract
Background and objectives Social distancing and quarantine implanted during the COVID-19 outbreak could have delayed the accession of oncologic patients to hospitals and treatments. This study analysed the management of sarcoma patients during this period in five Spanish hospitals. Design and methods Clinical data from adult sarcoma patients, soft tissue and bone sarcomas, managed during the COVID-19 outbreak, from 15 March to 14 September 2020 (Covid cohort), were retrospectively collected and time for diagnosis, surgery and active treatments were compared with sarcoma patients managed during the same pre-pandemic period in 2018 (Control cohort). Results A total of 126 and 182 new sarcoma patients were enrolled in the Covid and Control cohorts, respectively, who were mainly diagnosed as soft tissue sarcomas (81.0% and 80.8%) and at localized stage (80.2% and 79.1%). A diagnostic delay was observed in the Covid cohort with a median time for the diagnosis of 102.5 days (range 6-355) versus 83 days (range 5-328) in the Control cohort (p = 0.034). Moreover, a delay in surgery was observed in cases with localized disease from the Covid cohort with a median time of 96.0 days (range 11-265) versus 54.5 days (range 2-331) in the Control cohort (p = 0.034). However, a lower delay for neoadjuvant radiotherapy was observed in the Covid cohort with a median time from the diagnosis to the neoadjuvant radiotherapy of 47 days (range 27-105) versus 91 days (range 27-294) in the Control cohort (p = 0.039). No significant differences for adjuvant radiotherapy, neoadjuvant/adjuvant chemotherapy and neoadjuvant/adjuvant palliative chemotherapy were observed between both cohorts. Neither progression-free survival (PFS) nor overall survival (OS) was significantly different. Conclusion Delays in diagnosis and surgery were retrospectively observed in sarcoma patients during the COVID-19 outbreak in Spain, while the time for neoadjuvant radiotherapy was reduced. However, no impact on the PFS and OS was observed.
Collapse
Affiliation(s)
- Jaime Carrillo-García
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
| | - Serena Lacerenza
- Institute of Biomedicine of Seville (IBIS), HUVR-CSIC-University of Seville, Seville, Spain
| | - Nadia Hindi
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
- Medical Oncology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | | | - Gloria Marquina
- Department of Medical Oncology, Hospital Clínico San Carlos, School of Medicine, Complutense University (UCM), IdISSC, Madrid, Spain
| | - Juana María Cano Cano
- Medical Oncology Department, University Hospital General de Ciudad Real, Ciudad Real, Spain
| | | | - Alberto Rafael Sevillano Tripero
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
- Medical Oncology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Tania Luis García
- Department of Medical Oncology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain
| | | | - David S. Moura
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
| | - Marta Renshaw
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
| | - Jose L. Mondaza-Hernández
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
| | - Davide Di Lernia
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
| | - Antonio Gutierrez
- Department of Hematology, University Hospital Son Espases, Palma, Spain
| | - Javier Martin-Broto
- Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Reyes Católicos 2, Madrid 28040, Spain
- Medical Oncology Department, University Hospital General de Villalba, Madrid, Spain
- Medical Oncology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| |
Collapse
|
2
|
Putro YAP, Magetsari R, Mahyudin F, Basuki MH, Saraswati PA, Huwaidi AF. Impact of the COVID-19 on the surgical management of bone and soft tissue sarcoma: A systematic review. J Orthop 2023; 38:1-6. [PMID: 36875225 PMCID: PMC9957659 DOI: 10.1016/j.jor.2023.02.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Revised: 02/12/2023] [Accepted: 02/22/2023] [Indexed: 03/03/2023] Open
Abstract
Background The COVID-19 pandemic had greatly and negatively impacted health services including the management of bone and soft tissue sarcoma. As disease progression is time-sensitive, decision taken by the oncology orthopedic surgeon on performing surgical treatment determines the patient outcome. On the other hand, as the world tried to control the spread of COVID-19 infection, treatment re-prioritization based on urgency level had to be done which consequently affect treatment provision for sarcoma patients. Patient and clinician's concern regarding the outbreak have also inflicted on treatment decision making. A systematic review was thought to be necessary to summarize the changes seen in managing primary malignant bone and soft tissue tumors. Methods We performed this systematic review in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Statement. The review protocol had been registered on PROSPERO with submission number CRD42022329430. We included studies which reported primary malignant tumor diagnosis and its surgical intervention from March 11th, 2020 onwards. The main outcome is to report changes implemented by different centers around the world in managing primary malignant bone tumors surgically in response to the pandemic. Three electronic medical databases were scoured and by applying eligibility criteria. Individual authors evaluated the articles' quality and risk of bias using the Newcastle-Ottawa Quality Assessment Scale other instruments developed by JBI of the University of Adelaide. The overall quality assessment of this systematic review was self-evaluated using the AMSTAR (Assessing the Methodological Quality of Systematic Reviews) Checklist. Results There were 26 studies included in the review with various study designs, conveyed in almost all continents. The outcomes from this review are change in surgery time, change in surgery type, and change in surgery indication in patients with primary bone and soft tissue sarcoma. Surgery timing has been experiencing delay since the pandemic occurred, including delay in the multidisciplinary forum, which were all related to lockdown regulations and travel restrictions. For surgery type, limb amputation was preferred compared to limb-salvage procedures due to shorter duration and simpler reconstruction with better control of malignancy. Meanwhile, the indications for surgical management are still based on the patient's demographics and disease stages. However, some would stall surgery regardless of malignancy infiltration and fracture risks which are indication for amputation. As expected, our meta-analysis showed higher post-surgical mortality in patients with malignant bone and soft tissue sarcoma during the COVID-19 pandemic with odds ratio of 1.14. Conclusion Surgical management of patients with primary bone and soft tissue sarcoma has seriously been affected due to adjustments to the COVID-19 pandemic. Other than institutional restrictions to contain the infection, patient and clinician's decisions to postpone treatment due to COVID-19 transmission concern were also impactful in treatment course. Delay in surgery timing has caused higher risk of worse surgical outcome during the pandemic, which is aggravated if the patient is infected by COVID-19 as well. As we transition into a post-COVID-19 pandemic period, we expect patients to be more lenient in returning for their treatment but by then disease progression might have taken place, resulting in worse overall prognosis. Limitation to this study were few assumptions made in the synthesis of numerical data and meta-analysis only for changes in surgery time outcome and lack of intervention studies included.
Collapse
Affiliation(s)
- Yuni Artha Prabowo Putro
- Department of Orthopedics and Traumatology, RSUP Dr. Sardjito Hospital, Jl. Kesehatan Sendowo No.1, Sleman, 55281, D.I.Yogyakarta, Indonesia.,Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Jl. Farmako, Sendowo, Sekip Utara, Sleman, 55281, D.I.Yogyakarta, Indonesia
| | - Rahadyan Magetsari
- Department of Orthopedics and Traumatology, RSUP Dr. Sardjito Hospital, Jl. Kesehatan Sendowo No.1, Sleman, 55281, D.I.Yogyakarta, Indonesia.,Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Jl. Farmako, Sendowo, Sekip Utara, Sleman, 55281, D.I.Yogyakarta, Indonesia
| | - Ferdiansyah Mahyudin
- Department of Orthopaedic and Traumatology, Universitas Airlangga, Jl. Airlangga No.4 - 6, Gubeng, Surabaya, 60115, Jawa Timur, Indonesia.,Department of Orthopedics and Traumatology, RSUD Dr. Soetomo, Jl. Mayjen Prof. Dr. Moestopo No.6-8, Gubeng, Surabaya, 60286, Jawa Timur, Indonesia
| | - Muhammad Hardian Basuki
- Department of Orthopaedic and Traumatology, Universitas Airlangga, Jl. Airlangga No.4 - 6, Gubeng, Surabaya, 60115, Jawa Timur, Indonesia.,Department of Orthopedics and Traumatology, RSUD Dr. Soetomo, Jl. Mayjen Prof. Dr. Moestopo No.6-8, Gubeng, Surabaya, 60286, Jawa Timur, Indonesia
| | - Paramita Ayu Saraswati
- Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Jl. Farmako, Sendowo, Sekip Utara, Sleman, 55281, D.I.Yogyakarta, Indonesia
| | - A Faiz Huwaidi
- Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Jl. Farmako, Sendowo, Sekip Utara, Sleman, 55281, D.I.Yogyakarta, Indonesia
| |
Collapse
|
5
|
The role of specialist nurses in delivering effective care in a tertiary sarcoma referral service. J Clin Orthop Trauma 2021; 20:101501. [PMID: 34307019 PMCID: PMC8281648 DOI: 10.1016/j.jcot.2021.101501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 07/06/2021] [Accepted: 07/06/2021] [Indexed: 12/13/2022] Open
Abstract
Musculoskeletal sarcomas are rare cancers with an incidence of less than 1% of all cancers. Management of these tumors requires multidisciplinary care comprising of numerous specialists. Critical decisions following collaborative discussion among treating specialists followed by timely communication and starting prompt treatment are vital in delivering care in such rare sarcomas. While musculoskeletal surgeons, radiologists, and clinical oncologists are well known, the role of specialist nurses has been less described. They form a vital pillar in any tertiary sarcoma service by assisting in collaborative care, having consultations in nurse-led clinics, offering psychological support, imparting details of treatment to patient and helping in palliative care. This narrative review focuses on the role of trained specialist nurses in a tertiary sarcoma service and gives insight into their vital role in delivering timely, coordinated, effective care.
Collapse
|